NanoViricides to Present at Spartan Capital Investor Conference 2025

NanoViricides Inc. (NYSE American: NNVC), a clinical-stage developer of broad-spectrum antiviral drugs designed to prevent viral escape, announced it will present today, November 3, 2025, at 9:45 a.m. ET at the Spartan Capital Investor Conference in New York City. The company's presentation will focus on its innovative nanoviricide technology platform and ongoing clinical development programs. NanoViricides is creating special purpose nanomaterials for antiviral therapy based on intellectual property, technology and proprietary know-how of TheraCour Pharma Inc., with whom the company has a Memorandum of Understanding for the development of drugs for all antiviral infections.

The company's lead drug candidate is NV-387, a broad-spectrum antiviral drug planned for development as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Another advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The company is currently focused on advancing NV-387 into Phase II human clinical trials, though it cannot project an exact date for filing an Investigational New Drug application due to dependence on external collaborators and consultants. The company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

NanoViricides holds a worldwide exclusive perpetual license to TheraCour nanomedicine technology for several drugs with specific targeting mechanisms for the treatment of numerous human viral diseases including Human Immunodeficiency Virus, Hepatitis B and C viruses, Rabies, Herpes Simplex Virus, Varicella-Zoster Virus, Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The company intends to obtain additional licenses for RSV, Poxviruses, and/or Enteroviruses if initial research proves successful. The company has obtained broad, exclusive, sub-licensable field licenses to drugs developed in several licensed fields from TheraCour Pharma Inc.

The company's platform technology and programs are based on the TheraCour nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. As with any drug development efforts, there can be no assurance that any of the company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. The path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. Successful results against coronavirus in laboratory settings may not necessarily lead to successful clinical trials or a successful pharmaceutical product. The latest news and updates relating to NNVC are available in the company's newsroom at https://ibn.fm/NNVC. The full press release can be viewed at https://ibn.fm/cnCIM.